Sepracor Sues Synthon Over Oral Xyzal ANDA

Law360, New York (June 17, 2009, 12:00 AM EDT) -- A patent spat over antihistamine Xyzal has flared up again, with Belgian drugmaker UCB SA and its U.S. partner Sepracor Inc. launching a new suit against Synthon Pharmaceuticals Inc. over its planned generic copy of the new oral version of the drug.

Synthon’s Paragraph IV abbreviated new drug application filing constitutes infringement of their Xyzal patent, the companies say in a suit filed Wednesday in the U.S. District Court for the Eastern District of North Carolina.

The suit comes just over a year after the two...
To view the full article, register now.